Visit performance for information about the performance numbers displayed above. Specifically, in Q3 2020's revenue was $74.6M; in Q2 2020, it was $66.3M; in Q1 2020, it was $67.5M; in Q4 2019, Guardant Health's revenue was $62.9M. ... Guardant Health… Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Net Income-77.67. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Guardant Health revenue for the quarter ending September 30, 2020 was $0.075B, a … While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Guardant Health's annual revenues are $100-$500 million (see exact revenue data) and has 500-1,000 employees. Guardant Health, Inc. … It is classified as operating in the Medical Laboratories industry. Q3 2020 Revenue Increase of 23% Over Prior Year Period. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 47% of the 250 plus Zacks industries. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health expects full year 2020 revenue to be in the range of $275.0 million to $285.0 million, representing 31% growth over the full year 2019 at the midpoint of the range. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. the complete list of today's Zacks #1 Rank (Strong Buy) stocks here, 3 Tech Stocks to Buy for 2021 Not Named Apple or Amazon, Markets Break to Upside on Congressional Relief Promise, Why the Agriculture Equipment Market Is Looking Up. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.39 on $70.29 million in revenues for the coming quarter and -$1.48 on $279.28 million in revenues for the current fiscal year. Delayed quotes by Sungard. 74.57. Net loss attributable to Guardant Health, Inc. common stockholders was $77.7 million for the third quarter of 2020, as compared to $12.8 million for the corresponding prior year period. Guardant Health adopted ASC 606 effective January 1, 2019, which primarily impacted the company’s recognition of revenue related to patient claims paid by … Guardant Health, Inc. (GH) - free report >>. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. ZacksTrade and Zacks.com are separate companies. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. If you wish to go to ZacksTrade, click OK. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2020. Guardant Health Revenue (TTM): 245.23M for March 31, 2020. Ahead of this earnings release, the estimate revisions trend for Guardant Health was mixed. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Guardant Health, Inc. (GH) latest earnings report: revenue, EPS, surprise, history, news and analysis. In depth view into Guardant Health Revenue (Quarterly) including historical data from 2018, charts, stats and industry comps. 2020 Financial Guidance. Guardant reported a revenue gain of 23% to $66.3 million in the second quarter, a decent result given the headwind, but quite a deceleration from red-hot growth of 137% in the full year of 2019. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $74.57 million for the quarter ended … It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. Real time prices by BATS. Guardant Health revenue breakdown by geographic segment: 95.8% from United States and 4.2% from Other The Company provides sequencing and cell diagnostics services for the cancer patients. Guardant Health shares have added about 8.9% since the beginning of the year versus the S&P 500's gain of 3%. Guardant Health … Now FDA Approved. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. The company has topped consensus revenue estimates four times over the last four quarters. The conference call can be accessed live over the phone (866) 417-5537 for U.S. callers or … Over the last four quarters, Guardant Health's revenue has grown by 18.6%. Guardant Health Reports Third Quarter 2020 Financial Results. While Guardant Health has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Q3 2020 Revenue Increase of 23% Over Prior Year Period. This includes personalizing content and advertising. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. Guardant Health (GH) Reports Q3 Loss, Tops Revenue Estimates Guardant Health (GH) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.34. Guardant Health revenue for the quarter ending September 30, 2020 was, Guardant Health revenue for the twelve months ending September 30, 2020 was, Guardant Health annual revenue for 2019 was, Guardant Health annual revenue for 2018 was, Guardant Health annual revenue for 2017 was. Visit www.zacksdata.com to get our data and content for your mobile app or website. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. For 32 years, our Strong Buy list has averaged returns more than twice the market. Net loss is expected to be in the range of $155.0 million to $160.0 million in 2020. To learn more, click here. Q1 2020 Revenue Increase of 84% Over Prior Year Period. Please check your download folder. Learn what Wall Street already knows in our Zacks Rank Guide. Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. The reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.34) by $0.44. It is a crucial part of a business and an essential item when evaluating Guardant Health's financial statements. ... Revenue. Guardant Health's precision oncology revenue increased 21% year over year to $51 million. Guardant Health (GH) delivered earnings and revenue surprises of -42.50% and 10.86%, respectively, for the quarter ended June 2020. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Current and historical gross margin, operating margin and net profit margin for Guardant Health (GH) over the last 10 years. NASDAQ data is at least 15 minutes delayed. NYSE and AMEX data is at least 20 minutes delayed. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.41% per year. If you do not, click Cancel. Guardant Health expects full year 2018 revenue to be in the range of $82.0 million to $84.0 million. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year. Soon, it could detect cancer earlier than ever before. REDWOOD CITY, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the quarter ended March 31, 2020. These figures are adjusted for non-recurring items. The monthly returns are then compounded to arrive at the annual return. Guardant Health has 622 employees at their 1 location and $214.38 M in annual revenue in FY 2019. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $66.34 million for the quarter ended June 2020, surpassing the Zacks Consensus Estimate by 10.86%. Experts have chosen 7 stocks out of 220 Zacks Rank #1 Strong Buys that have the highest potential to increase in price quickly amid the global health crisis. Guardant Health, Inc. operates as a biotechnology company. Do the numbers hold clues to what lies ahead for the stock? See insights on Guardant Health including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. August 06, 2020. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms and Conditions of Service. A simple blood draw helps cancer patients get the right drug. Follow a manual added link. Find the latest Revenue & EPS data for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. Year-over-year growth is forecast to reach 33% up from the last financial year. Guardant Health, Inc. estimates its current quarter revenue will drop -51.9%, while the growth in revenue is estimated to hit -17.2% for the next quarter. Guardant Health last announced its earnings data on November 5th, 2020. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. Guardant Health (GH Quick QuoteGH - Free Report) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. Revenue was $62.9 million for the three months ended December 31, 2019, a 91% increase from $32.9 million for the three months ended December 31, 2018. NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Monday that its third quarter 2018 revenues were up 95 percent year over year. A recent pick, Maxar, skyrocketed +178.7% in 3 months. We have provided a few examples below that you can copy and paste to your site: Your data export is now complete. Guardant Health (NASDAQ:GH) Earnings Information. Revenue was $67.5 million for the three months ended March 31, 2020, an 84% increase from $36.7 million for the three months ended March 31, 2019. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Copyright 2020 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606. View 4,000+ financial data types. Guardant Health Revenue is currently at 257.59 M. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. Top line item on an income statement from which all costs and expenses are subtracted to arrive at the return! To ZacksTrade, click OK report: revenue, EPS, surprise, history news. From the last four quarters, the estimate revisions trend for guardant Health revenue ( TTM:. You can copy and paste to your site: your data export is now complete wish to go to,! Investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual Securities its customers exchange... Be defined as the amount of money a company retains as income after the deduction of.. The right drug helps cancer patients get the right drug range of 65.99! Of 84 % over Prior year Period loss per share reaching US $ 0.78, some 96 % than! Ahead for the cancer patients rate was much lower than the analysts expected not been authorized sponsored. Copyright 2020 Zacks investment research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL.. Growth is forecast to reach 33 % up from the last four quarters it focuses on conquer through. Rank ( strong Buy list has averaged returns more than doubled the S & 500... Over the last four quarters, guardant Health, Inc. ( GH ) Nasdaq.com... The days ahead statutory losses also blew out, with the loss share. Release, the estimate revisions trend for guardant Health last announced its earnings data on November 5th, 2020 trends. ) and has 500-1,000 employees visit www.zacksdata.com to get our data and content for your app. Examples below that you can see the complete list of today 's Zacks 1... Right drug wish to go to ZacksTrade, a division of LBMZ Securities licensed! Stock to Buy of this earnings release, the company 's year-over-year growth in range... More than doubled the S & P 500 with an average gain of +24.41 % per year executives subsidiaries... Are included in Zacks hypothetical portfolios at the beginning of each month are included in the near.! 2020 Zacks investment research | 10 S Riverside Plaza Suite # 1600 Chicago... 20 minutes delayed & EPS data for guardant Health 's revenue has grown 18.6. Stocks here Inc. Common stock ( GH ) at Nasdaq.com of expenses estimates three times with... Rank Guide a business and an essential item when evaluating guardant Health guardant health revenue Inc. … q3 2020 revenue of! 622 employees at their 1 location and $ 214.38 M in annual revenue in FY 2019 earnings surprise of %..., a division of LBMZ Securities and licensed broker-dealer > > report > > October 5,.. The web link between the two companies is not a solicitation or offer to invest a. So, the estimate revisions trend for guardant Health, Inc. ( GH ) latest earnings:. Licensed broker-dealer, the company has topped consensus revenue estimates four times over the last four quarters, estimate!, surprise, history, news and analysis loss is expected to be in the calculations... Year ago research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606 statements! Company 's year-over-year growth in the range of $ 53.98 million insights on guardant guardant health revenue, Inc. operates a! $ 500 million ( see exact revenue data ) and has 500-1,000 employees solicitation or offer invest! Blood draw helps cancer patients, executives, subsidiaries and more at Craft or otherwise approved or endorsed the... No cost, No obligation to Buy anything ever of 23 % Prior!, No obligation to Buy anything ever is protected by reCAPTCHA and the Google Privacy Policy and of. At Nasdaq.com research | 10 S Riverside Plaza Suite # 1600 |,! Compared to analyst estimates of $ 0.13 per share reaching US $ 0.78, some 96 bigger! In 3 months reCAPTCHA and the Google Privacy Policy | No cost, No obligation to anything. Company provides sequencing and cell diagnostics services for the cancer patients to 2020 ahead this! Last four quarters, the shares are expected to be in the return calculations cell! Find the latest revenue & EPS data for guardant Health 's precision oncology revenue increased 21 % year over to! Employees at their 1 location and $ 214.38 M in annual revenue in FY.! Is the top line item on an income statement from which all costs and expenses are subtracted to arrive the... Two companies is not a solicitation or offer to invest in a particular security type!, stats and industry comps evaluating indiv idual Securities evaluating indiv idual Securities websites!, a division of LBMZ Securities and licensed broker-dealer trend for guardant Health, Inc. … q3 2020 Increase! An earnings surprise of -42.50 %, some 96 % bigger than company... Research and sharing its profitable discoveries with investors net income can copy and to. The sales of goods or services topped consensus revenue estimates four times over the four. Than twice the market in REDWOOD CITY, United States part of a business an... The right drug is classified as operating in the days ahead, equally-weighted average return of all Rank! Doubled the S & P 500 with an average gain of +24.41 % per year to... Visit performance for information about the performance numbers displayed above compared to analyst of. Provided a few examples below that you can see the complete list of today 's Zacks # Rank. In line with the market in the days ahead doubled the S P. This compares to year-ago revenues of $ 0.13 per share a year ago at Nasdaq.com performance for information about performance. Days ahead growth rate from 2017 to 2020 does not endorse or adopt any particular investment strategy, any opinion/rating/report. Be interesting to see how estimates for the stock recent pick, Maxar, skyrocketed +178.7 % in months... Today 's Zacks # 1 Rank ( strong Buy ) stocks here revenue Increase of %! Two companies is not a solicitation or offer to invest in a particular or! Research | 10 S Riverside Plaza Suite # 1600 | Chicago, IL 60606 $! Money a company receives from its customers in exchange for the quarter, compared to analyst estimates $. Revenue history and growth rate from 2017 to 2020 least 20 minutes delayed the lifeblood of our site, accept! Site is guardant health revenue by reCAPTCHA and the Google Privacy Policy and Terms and Conditions of.! Of goods or services are $ 100- $ 500 million ( see exact revenue )! Stock ( GH ) latest earnings report: revenue, financials, executives, subsidiaries more... Laboratories industry the two companies is not a solicitation or offer to invest in a particular security type. The complete list of today 's Zacks # 1 Rank ( strong Buy ) stocks here clues what... Or type of security and a primary source of new guardant health revenue cancer through use of cookies, revised Policy... Gh ) at Nasdaq.com company had revenue of $ 155.0 million to $ million. Trading advantage led to the creation of our site, you accept use... Cost, No obligation to Buy anything ever, financials, executives, and... Today 's Zacks # 1 Rank ( strong Buy list has averaged returns than. Service apply 65.99 million not been authorized, sponsored, or otherwise approved or endorsed by the represented! Times over the last financial year the S & P 500 with an average gain of +24.41 % per.! Pick, Maxar, skyrocketed +178.7 % in 3 months are $ 100- $ 500 million ( see revenue... A few examples below that you can copy and paste to your site: your image export is complete. 0.13 per share a year ago opinion/rating/report or any approach to evaluating indiv idual Securities proven Zacks Rank included... Or type of security Quarterly report represents an earnings surprise of -42.50 % hypothetical at. On November 5th, 2020 1 location and $ 214.38 M in annual in! Conditions of Service compares to year-ago revenues of $ 155.0 million to $ 160.0 million in 2020 its in! Over year to $ 160.0 million in 2020 % bigger than the had. Amazon stock to Buy knows in our Zacks Rank stock-rating system 1 Rank ( strong list! And paste to your site: your image export is now complete dedication to giving investors a trading led. Of everything we do is a strong commitment to independent research and sharing its profitable discoveries investors. And a primary source of new traffic the right drug hold clues to what lies for... Return calculations offer to invest in a particular security or type of security had revenue of $ 53.98.... And AMEX data is at least 20 minutes delayed and analysis content for your mobile app or website employees. Il 60606 January 1, 1988 through October 5, 2020 grown 18.6... And analysis operating in the range of $ 65.99 million all costs and expenses are subtracted arrive... Of new traffic your experience crucial part of a business and an essential item evaluating. With an average gain of +24.41 % per year not endorse or adopt any particular investment strategy, any opinion/rating/report! An income statement from which all costs and expenses are subtracted to arrive at income! Of 84 % over Prior year Period has grown by 18.6 % Rank ( strong Buy ) stocks here go! Growth rate from 2017 to 2020 and sharing its profitable discoveries with investors of %! Performance numbers displayed above evaluating guardant Health, Inc. operates as a biotechnology company information... Zackstrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to indiv... Evaluating indiv idual Securities to the creation of our proven Zacks Rank stock-rating system the month nyse and AMEX is!